| Literature DB >> 28948200 |
Eyal Hassoun1, Mary Safrin1, Eitan Wineman1, Peretz Weiss2, Efrat Kessler1.
Abstract
This article provides a protocol for determination of human procollagen C-proteinase enhancer 1 (PCPE-1) concentrations by ELISA. The inter-assay and intra-assay coefficients of variability are given and so are the average plasma concentrations of PCPE-1 in healthy (control) individuals and liver fibrosis patients.Entities:
Keywords: Collagen biosynthesis; ELISA; Liver fibrosis; biomarkers
Year: 2017 PMID: 28948200 PMCID: PMC5602882 DOI: 10.1016/j.dib.2017.08.047
Source DB: PubMed Journal: Data Brief ISSN: 2352-3409
Fig. 1Standard curve for quantification of huPCPE-1 by sandwich ELISA. Increasing amounts of purified recombinant huPCPE-1 were adsorbed to wells pre-coated with a mouse monoclonal antibody to huPCPE-1. Bound PCPE-1 was detected using a rabbit polyclonal antibody to huPCPE-1 and quantified using an APA-conjugated goat anti rabbit IgG antibody. Each value represents mean±standard deviation (SD); n=2. mOD, Optical Density at 405 nm expressed in milli units.
Plasma concentrations of PCPE-1 in healthy (control) individuals.
| Individual | Gender | Age | PCPE-1 plasma concentration |
|---|---|---|---|
| C1 | F | 31 | 312.7±16.5 |
| C2 | F | 56 | 339.2±14.4 |
| C3 | M | 52 | 317.8±35.1 |
| C4 | M | 28 | 285.5±51.1 |
| C5 | M | 35 | 329.1±44.4 |
| Mean±SD | 316.9±20.3 |
This value is practically identical to the previously reported [4] value of 305 ng/ml (median; obtained by Western blotting of human sera samples and quantification of PCPE-1 band intensity), supporting the validity of our ELISA. C, control (healthy); F, female; M, male; Age is expressed in years. n=8 (two dilutions, each measured in duplicates on two different days).
Plasma concentrations of PCPE-1 in liver fibrosis patients.
| Patient | Gender | Age | PCPE-1 plasma concentration |
|---|---|---|---|
| P1 | F | 59 | 342.3±26.9 |
| P2 | F | 42 | 618.5±32.1 |
| P3 | M | 56 | 433.3±24.7 |
| P4 | M | 54 | 299.9±31.0 |
| P5 | M | 64 | 546.8±30.1 |
| Mean±SD | 448.1±134.3 |
P, patient; F, female; M, male; Age is expressed in years. n=4 (two dilutions each measured in duplicates).
Etiology, clinical features and MELD indexes of liver fibrosis patients.
| Patient | Cause | Complications | Additional disorders | MELD |
|---|---|---|---|---|
| P1 | HBV | Gastropathy, Controlled ascites | Hypertension, Obesity, Ovary cancer | 2 |
| P2 | HBV | Esophageal varices | None | 4 |
| P3 | HCV | Bleeding varices | Diabetes Mellitus Type 2 | 5 |
| P4 | HBV | Bleeding varices, Controlled ascites, Encephalopathy | Diabetes Mellitus Type 2 | 12 |
| P5 | HCV | None | Hypothyroidism | 9 |
P, patient; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-stage Liver Disease (a measure of mortality risk in patients with end-stage liver disease; http://www.mayoclinic.org/medical-professionals/model-end-stage-liver-disease).
Fig. 2PCPE-1 plasma concentrations in healthy (control) subjects and liver fibrosis patients. Data from Table 1, Table 2 (presented as the mean±standard deviation; n=5).
| Subject area | Biology, Biochemistry |
|---|---|
| More specific subject area | Plasma markers; Tissue Fibrosis |
| Type of data | Tables; Figures |
| How data was acquired | ELISA |
| Data format | Analyzed |
| Experimental | Measurement of PCPE-1 concentrations in human plasma using sandwich ELISA |
| Experimental | A procedure for determination of human PCPE-1 concentrations by ELISA was developed using a specific monoclonal antibody for immobilization of human PCPE-1 and a polyclonal rabbit antibody against human PCPE-1 for its detection. PCPE-1 concentrations in plasma samples from healthy individuals and liver fibrosis patients were determined using this assay. |
| Data source location | Tel Aviv University, Tel Aviv, Israel |
| Data accessibility | Data is provided within this article |